Bristol-Myers Squibb Co.

6 de nov. de 2026, 21:07 UTC

Bristol-Myers Squibb presented Phase 3 data for Camzyos in pediatric patients, while bearish sentiment grows with 8.29k puts traded ahead of earnings.

5 de nov. de 2026, 23:02 UTC

Bristol-Myers Squibb shares are declining in after-market hours amid a broader market downturn and concerns over semiconductor stocks affecting AI investments.

4 de nov. de 2026, 23:01 UTC

Bristol-Myers Squibb shares are trading modestly lower in after-market hours, having retraced from a brief peak shortly after the market closed.

3 de nov. de 2026, 23:01 UTC

Bristol-Myers Squibb Company has traded lower in after-market hours, retracing from an early high to roughly flat levels since Tuesday's close.

2 de nov. de 2026, 23:01 UTC

Bristol-Myers Squibb shares are trading modestly lower in after-market hours, having retraced from an earlier peak while remaining above its 20-day moving average.

30 de out. de 2026, 23:46 UTC

Bristol-Myers Squibb shares rose during after-market hours, remaining above their 20-day moving average, as the XLV ETF also gained from strong holdings.

29 de out. de 2026, 23:02 UTC

Bristol-Myers Squibb Company shares advanced modestly during after-market hours, supported by strength in the Pharmaceuticals sector amid positive US GDP growth data.

28 de out. de 2026, 22:01 UTC

Bristol-Myers Squibb Company is trading higher in after-market hours, reflecting notable strength alongside significant gains in the Pharmaceuticals sub-sector.

27 de out. de 2026, 23:01 UTC

Bristol-Myers Squibb partners with Anthropic to utilize AI models for clinical study analysis, potentially accelerating development assessments.

26 de out. de 2026, 20:07 UTC

Bristol-Myers Squibb reports positive Phase 3 PANKU-Lung01 study results for izalontamab brengitecan, showing median progression-free survival of 11.1 months.

23 de out. de 2026, 23:06 UTC

Bristol-Myers Squibb announces positive interim results from the Phase 3 PANKU-Breast01 study of izalontamab brengitecan in advanced breast cancer patients.

22 de out. de 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading following accelerated FDA approval for Zenbexus and a $2.3 billion investment in a Texas manufacturing campus.

21 de out. de 2026, 23:01 UTC

Bristol-Myers Squibb Co is declining in after-market trading, moving lower alongside the broader market while remaining near the midpoint of its one-month trading range.

20 de out. de 2026, 23:02 UTC

Bristol-Myers Squibb Co shares declined modestly in after-market trading, reflecting broader weakness in the Pharmaceuticals sub-sector.

19 de out. de 2026, 23:51 UTC

Bristol-Myers Squibb announces BioNTech SE will present new clinical data at the ESMO 2026 Congress, featuring 16 abstracts on various tumor types.

16 de out. de 2026, 23:01 UTC

Bristol-Myers Squibb Co shares advanced modestly in after-market trading following Friday's close, contrasting with recent stability within its one-month range.

15 de out. de 2026, 22:51 UTC

Bristol-Myers Squibb Co shares are trading modestly higher in after-market hours, following a notable gain earlier in the session.

14 de out. de 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are trading modestly lower in after-market hours, in line with a broader market decline amid rising inflation concerns and geopolitical tensions.

13 de out. de 2026, 20:08 UTC

Wells Fargo lowers Bristol-Myers Squibb price target to $60, maintaining Equal-Weight rating amid reassessment of valuations and broader market trends affecting pharmaceuticals.

12 de out. de 2026, 23:06 UTC

Bristol-Myers Squibb announces top-line results from the pivotal Phase 3 ALOFT-IPF trial for admilparant, a potential treatment for idiopathic pulmonary fibrosis.

9 de out. de 2026, 20:07 UTC

Bristol-Myers Squibb reports positive top-line results from the Phase 3 EXCALIBER-RRMM study for its Zenbexus therapy, aimed at treating multiple myeloma.

8 de out. de 2026, 23:40 UTC

Bristol-Myers Squibb announces positive topline results from the Phase 3 EXCALIBER-RRMM study evaluating ZENBEXUSTM in multiple myeloma patients.

7 de out. de 2026, 19:25 UTC

Bristol-Myers Squibb shares are advancing after Morgan Stanley raised its price target to $41.00, despite maintaining an Underweight rating.

6 de out. de 2026, 20:07 UTC

Bristol-Myers Squibb Co is advancing during Tuesday's trading session, recovering after five consecutive daily declines, though still below its 20-day moving average.

5 de out. de 2026, 23:05 UTC

Bristol-Myers Squibb Co is trading modestly higher in after-market hours following a series of lower finishes in prior sessions.

2 de out. de 2026, 23:00 UTC

Bristol-Myers Squibb Co is trading modestly lower in after-market hours, continuing a trend of declines over the last four trading sessions.

1 de out. de 2026, 23:40 UTC

Bristol-Myers Squibb Co is trading modestly higher in after-market hours following volatility and three consecutive lower daily closes.

30 de set. de 2026, 22:00 UTC

Bristol-Myers Squibb's CAMZYOS® receives FDA approval for treating obstructive hypertrophic cardiomyopathy, boosting shares modestly higher in after-market hours.

29 de set. de 2026, 23:01 UTC

Bristol-Myers Squibb Co's shares rose in after-market trading amid reports of a potential liver safety issue related to its phase 3 trials for admilparant.

28 de set. de 2026, 20:02 UTC

Bristol-Myers Squibb Co shares are higher as the company presents pivotal Phase 3 EXCALIBER-RRMM trial results for ZENBEXUS™ in combination therapy.